Sinobioway Medicine equity case second instance retrial: revocation of embezzlement charge, reduced prison term and fineWallstreetcn·Jan 2 at 11:15 AM002581+7.37%
Sinobioway Medicine's subsidiary Tianjin Sinobioway was suspended from production and sales by the Tianjin Municipal Drug Administration on April 22, 2025. Tianjin Sinobioway mainly engages in the production and sales of human interferon drugs, achieving an operating income of 216.5683 million yuan and a net profit of -14.0037 million yuan in 2024, accounting for 60.09% of the company's operating income and 9.8% of the consolidated net profit, respectively. This suspension has a significant impact on the company's operationsWallstreetcn·May 23, 2025 at 11:46 AM002581+7.37%
Sinobioway Medicine: The Tianjin Municipal Medical Products Administration has decided to implement risk control measures to suspend production and sales of Tianjin Sinobioway Biopharmaceutical Co., Ltd. The company's main business has been severely affected due to the suspension of production at Tianjin SinobiowayWallstreetcn·Apr 24, 2025 at 11:58 AM002581+7.37%
